10-Q: Xenetic Biosciences Reports First Quarter 2025 Financial Results, Cites Progress in DNase Technology

Xenetic Biosciences reports increased royalty revenue and reduced operating expenses in Q1 2025, while continuing to advance its DNase technology for cancer treatment.

Summary

• Xenetic Biosciences, Inc. filed its 10-Q report for the quarter ended March 31, 2025.
• The company is focused on advancing its DNase technology for treating cancers.
• Royalty revenue increased to $593,261 from $510,817 in the same period last year.
• Research and development expenses decreased to $879,029 from $944,321 year-over-year.
• General and administrative expenses decreased to $656,641 from $834,910 year-over-year.
• The net loss for the quarter was $903,141, compared to a net loss of $1,195,113 for the same period in 2024.
• The company had cash of $5,163,676 as of March 31, 2025, compared to $6,165,568 at the end of 2024.
• The company believes its existing resources will fund operations for at least twelve months but anticipates needing additional capital in the long-term.
• The company is exploring options for future financing, including equity offerings, debt financings, and corporate collaborations.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, there are improvements in revenue and expense management. The need for future capital raises introduces uncertainty.

Positives

• Royalty revenue increased by 16.1% year-over-year.
• Research and development expenses decreased by 6.9% year-over-year.
• General and administrative expenses decreased by 21.4% year-over-year.
• Net loss decreased by 24.4% year-over-year.
• The company is actively advancing its DNase technology with ongoing research collaborations.
• The company has existing resources to fund operations for at least the next twelve months.

Negatives

• The company incurred a net loss of $903,141 for the quarter ended March 31, 2025.
• The company has an accumulated deficit of $198.1 million as of March 31, 2025.
• The company anticipates needing additional capital in the long-term to pursue its business initiatives.
• The company's working capital decreased by $0.9 million during the quarter.

Risks

• The company has incurred substantial losses since its inception and expects to continue to incur operating losses in the near-term.
• The company's future financing is dependent on several factors, including progress in product development, ability to enter strategic arrangements, continued Nasdaq listing, and financial market conditions.
• The capital markets for the biotech industry can be highly volatile, making future financing uncertain.
• Geopolitical events and global conflicts may have an adverse effect on the economic markets and could impact the company's business, financial condition, and results of operations.
• The company's drug candidates have not received regulatory marketing authorization or approval in the U.S. or any other countries.

Future Outlook

The company believes its existing resources will be adequate to fund operations for at least twelve months but anticipates needing additional capital in the long-term to pursue its business initiatives, exploring options for future financing, including equity offerings, debt financings, and corporate collaborations.

Industry Context

Xenetic Biosciences is operating in the competitive biopharmaceutical industry, focusing on immune-oncology technologies. The company's DNase technology targets a novel approach to cancer treatment by addressing neutrophil extracellular traps (NETs). The company is receiving ongoing royalties pursuant to a license of its legacy PolyXen technology to an industry partner.

Comparison to Industry Standards

• It is difficult to compare Xenetic Biosciences directly to industry standards without more specific information on comparable companies and projects.
• However, the company's focus on DNase technology for cancer treatment aligns with the broader industry trend of developing novel immunotherapies.
• The company's royalty revenue stream provides a source of funding, which is common among biotechnology companies with licensed technologies.
• The company's ongoing research collaborations with Scripps Research and the University of Virginia are typical of early-stage biotechnology companies seeking to advance their technologies.

Related Party Transactions

• The Company paid PeriNess approximately $20,000 during the three months ended March 31, 2025.
• The Company entered into a Consulting Agreement with Dr. Dmitry Genkin, Chairman of our Board of Directors, to provide consulting services to the Company's DNase-based oncology program and paid Dr. Genkin approximately $0.1 million during the three months ended March 31, 2025.

Stakeholder Impact

• Shareholders: The company's financial performance and progress in developing its DNase technology will impact shareholder value.
• Employees: The company's ability to secure funding and advance its programs will impact job security and opportunities.
• Customers: The company's success in developing new cancer treatments will benefit patients and healthcare providers.
• Suppliers: The company's research and development activities will generate demand for supplies and services from vendors.
• Creditors: The company's ability to secure financing and generate revenue will impact its creditworthiness.

Next Steps

• Advance the systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
• Continue research and development activities with collaborative partners.
• Seek additional capital through public or private equity offerings, debt financings, corporate collaborations, or related party funding.

Key Dates

Keywords

DNase technology, Xenetic Biosciences, Royalty revenue, Research and development, Financial results, Biopharmaceutical, Immune-oncology, Cancer treatment, Clinical development, Net loss